Search Clinical Trials
 
By Condition
 
By Location (USA)
 
By Location (Other)
 
By Sponsor
 
Resources
 
Privacy Policy
 
About Us
Disclaimer
Treatment of Wegener's Granulomatosis with Cyclophosphamide Clinical Trials Data presented on Clinical Trials Search is not meant to be a substitute for qualified health advice, visits or treatment with a real mD. We are not doctors. Always consult your doctor about Treatment of Wegener's Granulomatosis with Cyclophosphamide conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Treatment of Wegener's Granulomatosis with Cyclophosphamide Clinical research trials and Treatment of Wegener's Granulomatosis with Cyclophosphamide healthcare trials happen in many of places across the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the effectivity of new drugs. The purpose of the studies / projects is to solve particular human medical questions. Clinical trials are a popular way for doctors, government agencies, and private sector companies to discover cures for all varieties of conditions, such as Treatment of Wegener's Granulomatosis with Cyclophosphamide. Treatment of Wegener's Granulomatosis with Cyclophosphamide Clinical Trials and other clinical trials allow volunteers to have health treatment alternatives before they are available to the masses. Some times the human subjects obtain treatment for without cost, and sometimes they are compensated for their time. Occasionally there is a cost for a Treatment of Wegener's Granulomatosis with Cyclophosphamide clinical trial. Test subjects oftentimes receive the most effective healthcare possible for their Treatment of Wegener's Granulomatosis with Cyclophosphamide condition. Dangers are a reality, however, and may include extra or frequent physician visits, healthcare dangers (possibly life-jeopardising), and/or the treatment being uneffective. Trials are federally governed with rigorous guidelines to protect clinical trials patients.

Home > "T" Clinical Trials Conditions > Treatment of Wegener's Granulomatosis with Cyclophosphamide

Treatment of Wegener's Granulomatosis with Cyclophosphamide



Treatment of Wegener's Granulomatosis with Cyclophosphamide

For Condition: Vasculitis,Wegener's Granulomatosis
Status: Completed
Sponsor(s): National Institute of Allergy and Infectious Diseases (NIAID) ,
Synopsis: The purpose of this protocol is to continue to treat patients with Wegener's granulomatosis who have already entered the study, and to treat new patients. The investigators will attempt to correlate the clinical response with specific immunosuppressive effects of drug administration. The investigators are accumulating data on the optimal duration and side effects of therapy.
Details: The purpose of the protocol is to continue to treat patients with Wegener's granulomatosis who have already entered the study, and to treat new patients. The investigators will attempt to correlate the clinical response with specific immunosuppressive effects of drug administration. The investigators are accumulating data on the optimal duration and side effects of therapy. Age Range: greater than 1 year
Eligibility:
Study Type:  Interventional, Treatment, Safety/Efficacy
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: Patients greater than 1 year of age with the clinical and pathological diagnosis of WG whose illness presents a risk of permanent disability or death. Examples of processes that impart risk of permanent disability or death include: peripheral and central nervous system disease, cardiac involvement, glomerulonephritis, and vascular comprise of gastrointestinal organs. No women who are pregnant or intend to become pregnant. No patients who have known malignancies. Patients must be HIV negative.
Total Enrollment: 200

Location and Contact Information:

National Institute of Allergy and Infectious Diseases (NIAID)
Bethesda,  Maryland,  20892
United States
 


Additional Information:
Study ID Numbers:  760042;  76-I-0042
Study Start Date: February 26, 1976
Record last reviewed: February 28, 2002
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00001155

Other Vasculitis Studies:
1. Cyclophosphamide and Prednisone Followed by Methotrexate To Treat Vasculitides

2. Etanercept for Wegener's Granulomatosis

3. Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases

4. Mycophenolate Mofetil to Treat Wegener's Granulomatosis and Related Vascular Inflammatory Conditions

5. Phase I Trial of Recombinant Human Interleukin-10 (SCH 52000) in Patients with Wegener's Granulomatosis

Related Studies:

Other Vasculitis Clinical Trials
Other Maryland Clinical Trials
Other Bethesda Clinical Trials

Treatment of Wegener's Granulomatosis with Cyclophosphamide
Modify your Search

  Other Vasculitis Clinical Trials
  Other Maryland Clinical Trials
  Other Bethesda Clinical Trials


Warning: include(/var/www/cgi-bin/traxis/counter.php) [function.include]: failed to open stream: No such file or directory in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103

Warning: include() [function.include]: Failed opening '/var/www/cgi-bin/traxis/counter.php' for inclusion (include_path='.:/usr/local/lib/php') in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103